On August 18th, 2020, member of the Production and Research Base of the State Key Laboratory of Respiratory Disease, Guangzhou N Biomedical Technology Co., Ltd and Hualan Biological Engineering, Inc. held a signing ceremony of the COVID-19 vaccine project in the lab. The two parties will carry out in-depth cooperation on the COVID-19 vaccine project. Hualan Biological Engineering, Inc. will carry out the thousand-level process research of large-scale production of COVID-19 vaccines (Recombinant Human Adv-p5), and strive to reach an annual production capacity of hundreds of millions of people. N Biomedical and Hualan Biological will jointly apply for the clinical trial of COVID-19 vaccines. The Phase I of clinical trials is planning to be carried out in Guangzhou, under the leadership of National Clinical Research Center for Respiratory Disease.

The cooperation contract of COVID-19 vaccine (Recombinant Human Adv-p5) was signed by An Kang, Chairman of Hualan Biological, and Chen Ling, Chairman of N Biomedical. Guests who attended the signing ceremony included Academician Nanshan Zhong, Director Shengxian Lu of Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Xiling Li, assistant director of the Biological Island (Guangdong Province) Laboratory, Jincun Zhao, deputy director of the State Key Laboratory of Respiratory Disease, and Rong Zhou, head of the production and research base. Academician Nanshan Zhong said in his speech: Vaccines may be the best way to stop the COVID-19 pandemic. Research and development of multiple vaccines in China is amongst the leading status globally, but it is not clear which vaccine and technology can achieve the best and the most long-lasting effect. China needs to support the clinical evaluation of multiple candidate vaccines and support the development of innovative vaccine manufacturers, in order to meet the huge needs domestically and internationally. With the unique design of N Biomedical’s COVID-19 vaccine, it is hoped that the cooperation between Hualan Biological and N Biomedical will advance to the clinical trials as soon as possible and provide China with one more kind of COVID-19 candidate vaccines.